Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774380 | 1.00 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL775459 | 1.00 | ALDH1A1 (0.35) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4040356 | 0.98 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL868850 | 0.75 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL3956646 | 0.75 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL2840915 | 0.75 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL292192 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8712083 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2844350 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL5934323 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012037258-A1 | PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | WO | claimed |
| EP-3085688-B1 | ADAMANTANE OR PINENE DERIVATIVES FOR USE IN THE TREATMENT OF CHLAMYDIALES INFECTIONS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10039727-B2 | Adamantane or pinene derivatives for use in the treatment of chlamydiales infections | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-08-07 | — | — | US | disclosed |
| US-20160310448-A1 | Adamantane or Pinene Derivatives for Use in the Treatment of Chlamydiales Infections | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-10-27 | — | — | US | disclosed |
| EP-3085688-A1 | ADAMANTANE OR PINENE DERIVATIVES FOR USE IN THE TREATMENT OF CHLAMYDIALES INFECTIONS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-1513825-B1 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Dept of Health and Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015192037-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BUSATH DAVID D (US) | 2015-12-17 | — | — | WO | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| EP-1392620-B1 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | AVANTIUM INT BV (NL) | 2007-05-23 | — | — | EP | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| US-20040186298-A1 | Novel use of sulfamic acids as resolving agent | AVANTIUM INTERNATIONAL B.V. (NL) | 2004-09-23 | — | — | US | disclosed |
| EP-1392620-A2 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | Avantium International B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100804-A2 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | AVANTIUM INTERNATIONAL, B.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| EP-1264814-A1 | Resolving agents based on amines | Avantium International B.V. (NL) | 2002-12-11 | — | — | EP | disclosed |
| EP-1037878-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999026927-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039727-B2 | Adamantane or pinene derivatives for use in the treatment of chlamydiales infections | ADRA1A, ADRA1B, ADRA1D | ALDH1A1 30/4885 |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | ALDH1A1 1876/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ALDH1A1 1277/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ALDH1A1 1277/4885 |
| US-20160310448-A1 | Adamantane or Pinene Derivatives for Use in the Treatment of Chlamydiales Infections | ADRA1A, ADRA1B, ADRA1D | ALDH1A1 21/4885 |
| US-20040186298-A1 | Novel use of sulfamic acids as resolving agent | HAO1, FPR1, DAO | ALDH1A1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.